General
Preferred name
leuprorelin
Synonyms
LEUPROLIDE ()
Enantone ()
LEUPROLIDE ACETATE ()
Leuprorelin Acetate ()
leuprorelin acetate, Camurus ()
LEUPROLIDE MESYLATE ()
Leuprorelin (acetate) ()
Leuprorelina ()
Leuprorelin slow release ()
Leuporelin ()
Leuproreline ()
(-)-leuprolide ()
TAP-144 FREE BASE ()
ABBOTT-43818 FREE BASE ()
NSC-377526 ()
CKD-841 ()
ABBOTT-43818 ()
Eligard ()
Leuplin ()
A-43818 ()
Lupron Depot Ped ()
Lupron Depot-Ped ()
Prostap ()
Lupaneta ()
Leuprorelin acetate ()
Lucrin ()
Tap-144-sr ()
Lutrate depot kit ()
Leuporelin acetate ()
Trenantone ()
Lupron Depot ()
Fensolvi kit ()
Lupron depot-ped kit ()
Lutrate depot ()
Leuprolide monoacetate ()
Viadur ()
Lupron ()
Carcinil ()
TAP-144 ()
Fensolvi ()
Eligard kit ()
Leuprorelin mesylate ()
Camcevi kit ()
Leuprorelin mesilate ()
Camcevi ()
P&D ID
PD047224
CAS
53714-56-0
74381-53-6
88793-81-1
Tags
available
drug
Approved by
EMA
FDA
First approval
1985
2021
Drug indication
metastatic prostate cancer
prostate carcinoma
Prostate cancer
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
The marketed formulation contains leuprolide acetate.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
13
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugCentral
DrugCentral Approved Drugs
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
85
Molecular Weight
1208.65
Hydrogen Bond Acceptors
14
Hydrogen Bond Donors
16
Rotatable Bonds
32
Ring Count
6
Aromatic Ring Count
4
cLogP
-1.23
TPSA
429.04
Fraction CSP3
0.53
Chiral centers
9.0
Largest ring
6.0
QED
0.02
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
GNRH Receptor
gonadotropin releasing factor hormone receptor agonist
Indication
prostate cancer
Target
GNRHR
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Hormone
Therapeutic Class
Hormone Therapy
Anticancer Agents
Source data
